tiprankstipranks
Trending News
More News >
Citius Oncology (CTOR)
NASDAQ:CTOR
US Market

Citius Oncology (CTOR) Stock Forecast & Price Target

Compare
131 Followers
See the Price Targets and Ratings of:

CTOR Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Citius
Oncology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CTOR Stock 12 Month Forecast

There Are No Analyst Ratings for CTOR In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

CTOR Financial Forecast

CTOR Earnings Forecast

Next quarter’s earnings estimate for CTOR is -$0.04 with a range of -$0.04 to -$0.04. The previous quarter’s EPS was -$0.06. CTOR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CTOR has Performed in-line its overall industry.
Next quarter’s earnings estimate for CTOR is -$0.04 with a range of -$0.04 to -$0.04. The previous quarter’s EPS was -$0.06. CTOR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CTOR has Performed in-line its overall industry.
No data currently available

CTOR Sales Forecast

Next quarter’s sales forecast for CTOR is $4.37M with a range of $4.37M to $4.37M. The previous quarter’s sales results were $0.00. CTOR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CTOR has Performed in-line its overall industry.
Next quarter’s sales forecast for CTOR is $4.37M with a range of $4.37M to $4.37M. The previous quarter’s sales results were $0.00. CTOR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CTOR has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
$6
Buy
460.75%
Upside
Reiterated
10/16/25
Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology's Lymphir
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
$6
Buy
460.75%
Upside
Reiterated
10/16/25
Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology's Lymphir
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Citius Oncology

3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-22.35%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -22.35% per trade.
1 Year
Success Rate
0/4 ratings generated profit
0%
Average Return
-29.98%
reiterated a buy rating 3 months ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.98% per trade.
2 Years
xxx
Success Rate
0/4 ratings generated profit
0%
Average Return
-29.98%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -29.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CTOR Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
1
3
3
2
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
3
3
2
0
In the current month, CTOR has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CTOR average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

CTOR Stock Forecast FAQ

What is CTOR’s average 12-month price target, according to analysts?
Currently, no data Available
What is CTOR’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CTOR, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is CTOR a Buy, Sell or Hold?
      Currently, no data Available
      What is Citius Oncology’s price target?
      Currently, no data Available
      What do analysts say about Citius Oncology?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of CTOR?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.